Health Care & Life Sciences » Biotechnology | Portola Pharmaceuticals Inc.

Portola Pharmaceuticals Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
83,352.00
137,125.00
226,505.00
268,113.00
285,620.00
350,544
Depreciation, Depletion & Amortization
1,359.00
1,542.00
1,311.00
1,924.00
2,410.00
3,102
Other Funds
-
-
-
1,700.00
-
78,451
Funds from Operations
75,453.00
122,433.00
199,527.00
234,653.00
223,944.00
268,991
Changes in Working Capital
11,838.00
21,727.00
7,727.00
38,198.00
1,181.00
57,067
Net Operating Cash Flow
63,615.00
100,706.00
207,254.00
196,455.00
225,125.00
326,058
Capital Expenditures
933.00
1,629.00
4,746.00
1,864.00
6,236.00
Purchase/Sale of Investments
119,803.00
137,523.00
58,032.00
142,407.00
222,536.00
Net Investing Cash Flow
120,736.00
139,152.00
53,286.00
140,543.00
228,772.00
Issuance/Reduction of Debt, Net
-
-
-
58,000.00
47,444.00
Net Financing Cash Flow
248,511.00
179,599.00
283,282.00
57,741.00
446,980.00
Net Change in Cash
64,160.00
60,259.00
129,315.00
1,829.00
6,917.00
Free Cash Flow
64,548.00
102,335.00
212,000.00
198,319.00
226,361.00
Change in Capital Stock
248,511.00
179,599.00
283,282.00
1,441.00
399,536.00
Miscellaneous Funds
-
-
1.00
-
-

About Portola Pharmaceuticals

View Profile
Address
270 East Grand Avenue
South San Francisco California 94080
United States
Employees -
Website http://www.portola.com
Updated 07/08/2019
Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis and hematologic disorders, and inflammation. Its FDA-approved medicines include Bevyxxa (betrixaban), the oral, once-daily Factor Xa inhibitor, and Andexxa coagulation factor Xa (recombinant), inactivated-zhzo, the antidote for the Factor Xa inhibitors rivaroxaban and apixaban. The company was founded by Charles J.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.